Low-Dose Steroids, Not Vasopressin, Linked to More Organs From Brain-Dead Donors

Organ transplantation saves thousands of lives each year, yet the global supply of transplantable organs falls dramatically short of demand. Only about ten percent of the world’s transplant needs are currently met, and intensive care units around the world are searching for ways to squeeze more life-saving organs from every generous donor. Now, a large multicenter study from Japan offers a striking and potentially practice-changing insight: a modest dose of a common steroid, rather than the widely used hormone vasopressin, appears to be the pharmacological intervention most consistently associated with harvesting more organs from brain-dead donors.

The research, drawn from the Japan Comprehensive Process for End-of-Life Care and Organ Donation after Brain Death, or J-RESPECT, cohort, analyzed 204 brain-dead organ donors across 16 tertiary emergency and critical care centers between July 2010 and December 2023. These cases represented 21.8 percent of all brain-dead organ donations nationwide during the study period, making the dataset an unusually comprehensive window into real-world Japanese donor management. The findings were published in the journal Neurocritical Care by a team led by Tetsuya Yumoto of Okayama University, together with the J-RESPECT study group.

The physiological challenge that the study addresses is formidable. Brain death unleashes a cascade of devastating disturbances throughout the body: autonomic storm, hemodynamic collapse, hormonal deficiencies, and systemic inflammation. The loss of hypothalamic and pituitary function frequently triggers diabetes insipidus, in which the kidneys excrete enormous volumes of dilute urine, destabilizing blood pressure and fluid balance. A Korean nationwide study cited by the authors reported that cardiac arrest strikes 22.2 percent of donors during the brain death determination process itself. Every episode of cardiovascular instability threatens the viability of organs that might otherwise save lives downstream.

To combat this storm, intensivists around the world routinely deploy hormone replacement therapy, most commonly vasopressin to control diabetes insipidus and support blood pressure, and corticosteroids to stabilize hemodynamics and blunt the inflammatory response. Yet the evidence base for both practices has been surprisingly thin. A previous meta-analysis concluded that existing clinical evidence was insufficient to confirm or refute whether corticosteroids improve donor or recipient outcomes, and observational studies of vasopressin have generally evaluated the drug in isolation rather than alongside the other therapies donors typically receive.

The Japanese team set out to disentangle these overlapping treatments. Donors were classified into a high-yield group of six or more procured organs and a low-yield group of five or fewer, based on the cohort median of six organs. Lungs and kidneys were each counted as two organs when both sides were procured, while a liver counted as one even if split among multiple recipients. The researchers then applied generalized estimating equations, a statistical framework that accounts for the fact that donor management practices cluster within institutions, adjusting for age, sex, out-of-hospital cardiac arrest, admission Sequential Organ Failure Assessment score, catecholamine use, time from admission to procurement, and, critically, the number of organs the family had requested.

The results were unambiguous on one point and surprising on another. Low-dose methylprednisolone, defined as less than 15 milligrams per kilogram per day in methylprednisolone equivalents, was associated with nearly triple the odds of high-yield organ procurement compared with no corticosteroid use, with an adjusted odds ratio of 2.86 and a 95 percent confidence interval of 1.45 to 5.63. High-dose methylprednisolone at or above 15 milligrams per kilogram per day showed no such association. Vasopressin dose, categorized across four exposure levels, was not independently associated with overall organ yield after adjustment. The number of organs requested by the donor’s family was also independently linked to high-yield procurement, underscoring how consent conversations shape the eventual harvest.

In exploratory organ-specific analyses, the picture became even more nuanced. High-dose methylprednisolone was associated with dramatically higher odds of left lung donation, with an odds ratio of 8.99, while moderate-dose vasopressin was associated with lower odds of right lung donation. No consistent associations emerged for the heart, liver, or pancreas, and kidney models were not fitted because donation was nearly universal. The authors emphasize that these organ-specific findings are hypothesis-generating, particularly given the multiple comparisons performed, but they note that the lung signal is biologically plausible: corticosteroids may attenuate the inflammatory lung injury that accompanies brain death, a mechanism supported by earlier experimental and clinical work.

The study’s sensitivity analyses strengthened the central conclusion. When the yield threshold was shifted to five versus four organs, low-dose methylprednisolone remained significantly associated with the outcome, and when organ count was treated as a continuous variable, low-dose methylprednisolone was independently associated with an additional 0.46 organs procured per donor. Adjusting for the study period and replacing the admission-to-procurement interval with the brain-death-determination-to-procurement interval produced similar results. Vasopressin, by contrast, never emerged as an independent predictor of yield, suggesting that its principal benefit may lie in preserving donor physiology, controlling diabetes insipidus, and reducing catecholamine requirements rather than directly increasing the number of organs recovered.

The Japanese context adds an important dimension to the findings. The median time from hospital admission to organ procurement was 10 days, far longer than is typical in Western countries, reflecting Japan’s legally mandated process of two independent brain death determinations performed at least six hours apart, along with detailed family consent specifying which organs may be donated. During most of the study period, patients on extracorporeal membrane oxygenation could not be legally declared brain-dead under Japanese guidelines, a restriction lifted only on January 1, 2024. The scarcity of donation is itself striking: of 906 designated institutions, only 297 had ever performed a brain-dead donation procedure as of 2023, averaging roughly three cases per institution over twelve years.

The authors are careful to frame their conclusions cautiously. The study lacked recipient graft survival data, could not capture the reasons organs were not procured, and included only donors from whom at least one organ was ultimately recovered. Illness severity was adjusted only through the admission SOFA score, and variables such as target blood pressure, fluid balance, and infections were not available. Because the organ-specific analyses were exploratory and unadjusted for multiple comparisons, they require confirmation in prospective studies. Nevertheless, the message for the transplant community is clear and potentially consequential: when it comes to maximizing the gift that a brain-dead donor can give, the dose of corticosteroid may matter more than the drugs have been given credit for, and the humble low-dose regimen, rather than aggressive high-dose protocols or vasopressin titration, may be the key to unlocking more organs from every act of extraordinary generosity.

Subject of Research: Associations of vasopressin and corticosteroid therapy with organ yield in brain-dead organ donors

Article Title: Associations of Vasopressin and Corticosteroid Therapy with Organ Yield in Brain-Dead Donors: A Multicenter Cohort Study in Japan

Article References: Yumoto, T., Naito, H., Hongo, T., Obara, T., Nojima, T., Tsukahara, K., Hayakawa, M., Yokobori, S., Nishiyama, K., Atsumi, T., Tasaki, O., Yamamura, Y., Yorifuji, T., Nakao, A., and J-RESPECT study group, Tsurukiri, J., Hayamizu, M., Murahashi, S., Hayashi, M., … Hosotani, M. (2026). Associations of Vasopressin and Corticosteroid Therapy with Organ Yield in Brain-Dead Donors: A Multicenter Cohort Study in Japan. Neurocritical Care. https://doi.org/10.1007/s12028-026-02645-6

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02645-6

Keywords: brain death, organ donation, organ transplantation, vasopressin, methylprednisolone, corticosteroids, hormone replacement therapy, donor management, critical care, J-RESPECT, organ yield, Japan